CytoDyn Announces Significantly Improved Response Rate at Higher Dose of PRO 140 in HIV Phase 3 Monotherapy Trial Jul 30, 2018 6:00am EDT
CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial Jul 16, 2018 6:00am EDT
CytoDyn Announces Leadership Changes to Align with Expanded Focus of PRO 140 to Cancer and Immunological Disorders Jul 12, 2018 4:15pm EDT
CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders Jul 12, 2018 4:05pm EDT
New Research Supports Potential for CytoDyn’s PRO 140 to Inhibit Breast Cancer Metastasis Jun 26, 2018 6:00am EDT
CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy Jun 22, 2018 6:00am EDT
CytoDyn ASM Poster Presentation June 9, 2018, at ASM Microbe 2018, Atlanta, GA Jun 11, 2018 6:00am EDT
